Pharmaceutical agents for treatment of leishmaniasis: a patent landscape

References

• Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. Leishmaniasis: a review. F1000Res. 2017;6:1–15.
   Google Scholar
• Menezes J, Sampaio Guedes C, Petersen A, et al. Advances in development of new treatment for leishmaniasis. Biomed Res Int. 2015;2015:1–11.
   Web of Science ®Google Scholar
• Hendrickx S, Caljon G, Maes L. Need for sustainable approaches in antileishmanial drug discovery. Parasitol Res. 2019;118(10):2743–2752.
   PubMed Web of Science ®Google Scholar
• Ponte-Sucre A, Gamarro F, Dujardin JC, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017;11:1–24.
   Web of Science ®Google Scholar
• Bekhit AA, El-Agroudy E, Helmy A, et al. Leishmania treatment and prevention: natural and synthesized drugs. Eur J Med Chem. 2018;160:229–244.
   PubMed Web of Science ®Google Scholar
• Braga SS. Multi-target drugs active against leishmaniasis: a paradigm of drug repurposing. Eur J Med Chem. 2019;183:111660.
   PubMed Web of Science ®Google Scholar
• Chakravarty J, Sundar S. Current and emerging medications for the treatment of leishmaniasis. Expert Opinion on Pharmacotherapy. 2019;20(10):1251–1265.
   PubMed Web of Science ®Google Scholar
• Machado-Silva A, Guimarães PPG, Tavares CAP, et al. New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: a patent landscape. Expert Opin Ther Pat. 2015;25:247–260.
   PubMed Web of Science ®Google Scholar
• Chow LM-C. Synthesis and use of amine-containing flavonoids as potent anti-leishmanial agentes. US 9562037. 2017.
   Google Scholar
• Araujo MV, Queiroz AC, Silva JFM, et al. Flavonoids induce cell death in Leishmania amazonensis: in vitro characterization by flow cytometry and Raman spectroscopy. Analyst. 2019;144:5232–5244.
   PubMed Web of Science ®Google Scholar
• Boniface PK, Ferreira EI. Flavonoids as efficient scaffolds: recent trends for malaria, leishmaniasis, chagas disease, and dengue. Phytother Res. 2019;33:2473–2517.
   PubMed Web of Science ®Google Scholar
• Fonseca-Berzal C, Ibanez-Escribano A, Vela N, et al. Antichagasic, leishmanicidal, and trichomonacidal activity of 2-benzyl-5-nitroindazole-derived amines. ChemMedChem. 2018;13:1246–1259.
   PubMed Web of Science ®Google Scholar
• Escario Garcia-Trevijano JA. Amines derived from 2-benzyl-5-nitroindazole with antiprotozoal properties against Trypanosoma, Leishmania and Trichomonas. WO 2019077174. 2019.
   Google Scholar
• James MT, George TM. Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis. EP 3247713. 2017.
   Google Scholar
• Karrouchi K, Radi S, Ramli Y, et al. Synthesis and pharmacological activities of pyrazole derivatives: a review. Molecules. 2018;23:1–86.
   Web of Science ®Google Scholar
• Gilbert IH, Thomas MG. Antileishmanial pyrazoloyirimidines. WO 2016116752. 2016.
   Google Scholar
• Miles TJ, Thomas MG. Pyrazolo[3,4-d]pyrjmidin derivative and its use for the treatment of leishmaniasis. WO 2016116563. 2016.
   Google Scholar
• Deeks ED. Fexinidazole: first global approval. Drugs. 2019;79:215–220.
   PubMed Web of Science ®Google Scholar
• Pollmeier M, Blair JJ. Method for treating and curing leishmaniosis using fexinindazole. WO 2014121064. 2014.
   Google Scholar
• Kalpana B. Novel substituted benzocycloalkyl azole derivatives as antileishmanial agents. IN271474. 2016.
   Google Scholar
• Camarasa R, Maria J. Triazole-phenyl-thiazole heterocycles as innovative inhibitors of tryphanothione redutase and their use leishmanicides. WO 2019122113. 2019.
   Google Scholar
• Velez-Bernal ID. Cream formulation with amphotericin b and oil in water useful for topical application to mucous tissue and skin against diseases produced by leishmaniasis. US 9801895. 2017.
   Google Scholar
• Gillet D. Adamantane or bicyclic monoterpenoid derivatives for use in the treatment of leishmaniasis. WO 2019086514. 2019.
   Google Scholar
• Bahmani M, Saki K, Ezatpour B, et al. Leishmaniosis phytotherapy: review of plants used in Iranian traditional medicine on leishmaniasis. Asian Pac J Tropical Biomedicine. 2015;5:695–701.
   Google Scholar
• Scotti MT, Scotti L, Ishiki H, et al. Natural products as a source for antileishmanial and antitrypanosomal agents. Comb Chem High Throughput Screening. 2016;19:537–553.
   PubMed Web of Science ®Google Scholar
• Maurya R, Chandrasekaran S. A novel synergistic composition for the treatment of visceral leishmaniasis. WO 2017046778. 2017.
   Google Scholar
• Baker BJ, Witowski CG, Maschek JA, et al. Diterpenoide membranolide compounds having anti-leishmania acitivity and uses thereof. US 20160030388. 2016.
   Google Scholar
• Auclair C, Fellous E, Le Pape P, et al. Topical compositions for the treatment of cutaneous leishmaniasis. WO 2019043212. 2019.
   Google Scholar
• Hajaji S, Sifaoui I, Lopez-Arencibia A, et al. Leishmanicidal activity of alpha-bisabolol from Tunisian chamomile essential oil. Parasitol Res. 2018;117:2855–2867.
   PubMed Web of Science ®Google Scholar
• Corpas-Lopez V, Merino-Espinosa G, Acedo-Sanchez C, et al. Effectiveness of the sesquiterpene (-)-alpha-bisabolol in dogs with naturally acquired canine leishmaniasis: an exploratory clinical trial. Vet Res Commun. 2018;42:121–130.
   PubMed Web of Science ®Google Scholar
• Aruna G. Immunotoxins: a review of their use in cancer treatment. J Stem Cells Regen Med. 2006;1:31–36.
   PubMedGoogle Scholar
• Cenini P, Bolognesi A, Stripe F. Ribosome‐inactivating proteins from plants inhibit ribosome activity of Trypanosoma and Leishmania. J Protozool. 1998;3:384–387.
   Google Scholar
• Barth S, Thepen T, Barral-Netto M, et al. An Immunotoxin for use in the treatment of leishmaniasis. WO 2016116550. 2016.
   Google Scholar
• Qvit N, Mochly-Rosen D, Schechtman D, et al. Compositions and methods for specific inhibition of Leishmania receptor for activated c-kinase (lack). WO 2014036198. 2014.
   Google Scholar
• Sereno D, Lemesre JL. Use of an enzymatic micromethod to quantify amastigote stage of Leishmania amazonensis in vitro. Parasitol Res. 1997;83:401–403.
   PubMed Web of Science ®Google Scholar
• de Souza A, Marins DSS, Mathias SL, et al. Promising nanotherapy in treating leishmaniasis. Int J Pharm. 2018;547:421–431.
   PubMedGoogle Scholar
• Islan GA, Duran M, Cacicedo ML, et al. Nanopharmaceuticals as a solution to neglected diseases: is it possible? Acta Trop. 2017;170:16–42.
   PubMed Web of Science ®Google Scholar
• Kosey D, Singh S. Computational design of molecular motors as nanocircuits in leishmaniasis. F1000Res. 2017;6:94.
   PubMedGoogle Scholar
• Nazir S, Rabbani A, Mehmood K, et al. Antileishmanial activity and cytotoxicity of ZnO-based nano-formulations. Int J Nanomedicine. 2019;14:7809–7822.
   PubMed Web of Science ®Google Scholar
• Britti D, Cosco D, Fresta M, et al. Nanoparticulate systems for vehiculating drugs for the treatment of Leishmania infection-related pathologies. WO 2015177820. 2015.
   Google Scholar
• Frezard FJG, Azevedo EG, Bibeiro RR, et al. Pharmaceutical composition containing conventional liposomes and prolonged-circulation liposomes for the treatment of visceral leishmaniasis. US 2015/0306035. 2015.
   Google Scholar
• World Health Organization (WHO). Leishmaniasis. [ cited 2020 Feb 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
   Google Scholar
• National Library of Medicine. Medications for leishmaniasis. [ cited 2020 Feb 7]. Available from: https://www.drugs.com/condition/leishmaniasis.html
   Google Scholar
• Drugs for Neglected Diseases initiative (DNDi). Towards a new generation of treatments for leishmaniasis. [ cited 2020 Feb 7]. Available from: https://www.dndi.org/wp-content/uploads/2018/12/DNDi_Leishmaniasis_2018.pdf
   Google Scholar
• Pijpers J, Boer ML, Essink DR, et al. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia – A review and meta-analysis. PLoS Negl Trop Dis. 2019;13:1–14.
   Web of Science ®Google Scholar
• Singh N, Kumar M, Singh RK. Leishmaniasis: current status of available drugs and new potential drug targets. Asian Pac J Trop Med. 2012;5:485–497.
   PubMed Web of Science ®Google Scholar
• Ghorbani M, Farhoudi R. Leishmaniasis in humans: drug or vaccine therapy? Dovepress. 2018;12:25–40.
   Google Scholar